Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The novel HIV capsid inhibitor also shows promise for previously untreated people.
Lenacapavir shows promise for long-acting HIV treatment and prevention.
Until now, researchers believed that the replication capsid’s main function was to hold viral genetic material.
Gilead’s HIV capsid inhibitor might need dosing only every six months
Studies indicate that there is a very low likelihood that people with HIV have preexisting resistance to the medication.
The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
The antiretroviral GS-6207 is injected under the skin and would need to be combined with other meds to fully suppress HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.